Hemab Aps
Clinical trials sponsored by Hemab Aps, explained in plain language.
-
New hope for bleeding disorder: experimental drug HMB-002 enters human testing
Disease control Recruiting nowThis study tests a new medicine, HMB-002, in 108 adults with von Willebrand disease (types 1 and 2). The goal is to check if the drug is safe, how the body processes it, and whether it helps control bleeding. Participants will receive either one or several doses of the drug, and …
Phase: PHASE1, PHASE2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated May 26, 2026 05:43 UTC
-
New hope for rare bleeding disorder: Single-Dose drug trial begins
Disease control Recruiting nowThis study tests a new drug called sutacimig in 18 adults with a rare bleeding disorder (congenital Factor VII deficiency). Participants receive a single dose to see if it is safe and helps control bleeding. The goal is to find a better treatment option for those with severe blee…
Phase: PHASE2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New study aims to map Real-World bleeding in von willebrand disease
Knowledge-focused Recruiting nowThis study is gathering information about bleeding episodes, quality of life, and treatment use in 200 people with von Willebrand disease (VWD). Participants will report their bleeding events and complete surveys over time. The data will help researchers understand the daily impa…
Sponsor: Hemab ApS • Aim: Knowledge-focused
Last updated May 04, 2026 16:22 UTC